Aplastic Anemia as a Roadmap for Bone Marrow Failure: An Overview and a Clinical Workflow.
Antonio Giovanni SolimandoCarmen PalumboMary Victoria PragnellMarkus KrebsAntonella ArgentieroMarkus KrebsPublished in: International journal of molecular sciences (2022)
In recent years, it has become increasingly apparent that bone marrow (BM) failures and myeloid malignancy predisposition syndromes are characterized by a wide phenotypic spectrum and that these diseases must be considered in the differential diagnosis of children and adults with unexplained hematopoiesis defects. Clinically, hypocellular BM failure still represents a challenge in pathobiology-guided treatment. There are three fundamental topics that emerged from our review of the existing data. An exogenous stressor, an immune defect, and a constitutional genetic defect fuel a vicious cycle of hematopoietic stem cells, immune niches, and stroma compartments. A wide phenotypic spectrum exists for inherited and acquired BM failures and predispositions to myeloid malignancies. In order to effectively manage patients, it is crucial to establish the right diagnosis. New theragnostic windows can be revealed by exploring BM failure pathomechanisms.
Keyphrases
- bone marrow
- stem cells
- end stage renal disease
- mesenchymal stem cells
- chronic kidney disease
- electronic health record
- newly diagnosed
- ejection fraction
- young adults
- dendritic cells
- peritoneal dialysis
- acute myeloid leukemia
- prognostic factors
- genome wide
- magnetic resonance imaging
- gene expression
- magnetic resonance
- allogeneic hematopoietic stem cell transplantation
- big data
- iron deficiency
- copy number
- contrast enhanced